teaserproduits : BT-001

BT-001 is an armed oncolytic virus expressing an anti-CTLA4 and GM-CSF antibody, from the Invir.IO® platform.

It has been evaluated in a Phase 1/2a multicenter, open label, dose-escalation study as a single agent and in combination with pembrolizumab* in solid tumors after intratumoral administration.

*KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

More information on clinicaltrial.gov

A collaboration with BioInvent

Read more on BT-001

BT-001 mode of action